It's an Exciting Time to Treat Obesity: New Meds and What’s to Come
We are living through a genuine revolution in obesity medicine. For decades, we had very few effective tools. Now, in the span of just a few months, we've gained FDA-approved oral GLP-1 pills, a first-in-class triple-hormone agonist breaking records in clinical trials, and an entirely new class of medication that targets the muscle side of the equation. More options mean more personalization — and better outcomes for my patients.
As a board-certified Endocrinologist and Obesity Medicine specialist, this is the part of my work I find most energizing: watching the science catch up to what patients deserve. Let me walk you through what's new, what's coming, and why it matters for you.
The Era of the GLP-1 Pill Has Arrived
For years, GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) have been among the most effective weight loss medications ever developed — but they required weekly injections. That changed in a big way at the end of 2025 and into 2026.
Oral Wegovy (semaglutide 25 mg) was FDA-approved in December 2025 as the first oral GLP-1 approved specifically for weight management. In clinical trials, patients achieved an average of 16.6% body weight loss at 64 weeks, with one in three participants losing 20% or more. That is comparable to the injectable form. The pill is taken once daily first thing in the morning on an empty stomach, with a 30-minute wait before eating — so it works best for patients who can build that into their morning routine.
Then in April 2026, Eli Lilly received FDA approval for Foundayo (orforglipron) — and this one is structurally different in a way that matters practically. Foundayo is a small non-peptide molecule, which means it can be taken at any time of day, with or without food, with no waiting period and no water restrictions. No injection, no fasting window, no refrigeration required at any stage. For the patient who travels constantly, hates needles, or simply needs something that fits into a less-than-perfect morning — this is a genuinely different kind of option. Eli Lilly has also priced it aggressively, with savings programs bringing the cost as low as $25 per month for eligible patients.
These two pills are not just convenient — they are expanding access to effective treatment for people who previously couldn't or wouldn't pursue injectable therapy.
Retatrutide: The Triple-Hormone Agonist Rewriting the Record Books
If the oral pills are exciting, retatrutide is genuinely jaw-dropping — and I say that as a clinician who tries not to overuse that word.
Developed by Eli Lilly, retatrutide is a once-weekly injectable that simultaneously activates three hormone receptors: GLP-1, GIP, and glucagon. Our current best-in-class injectable, tirzepatide, activates two (GLP-1 and GIP). Adding glucagon receptor activation appears to dramatically increase energy expenditure — essentially turning up your metabolism in addition to reducing appetite.
In the Phase 3 TRIUMPH-4 trial results released in December 2025, retatrutide produced an average of 28.7% body weight loss at 68 weeks. That is the highest weight loss ever recorded in a Phase 3 obesity trial in history. Participants in the highest dose group lost an average of 71.2 pounds. For context, tirzepatide — which itself broke records — produced about 22.5% weight loss in its pivotal studies. Nearly 60% of retatrutide participants lost 25% or more of their total body weight.
Seven additional Phase 3 trials are expected to report results throughout 2026, covering type 2 diabetes, sleep apnea, cardiovascular outcomes, and more. If those data hold, we could see an FDA submission by late 2026 and potential approval in 2027.
Retatrutide is not yet available outside of clinical trials. Please be very cautious of any compounding pharmacy or online service claiming to offer it — it remains investigational, and I will be watching the remaining trial results closely.
Bimagrumab: Rethinking What "Weight Loss" Actually Means
This is the one I get most excited explaining to patients, because it addresses something that has always concerned me about rapid weight loss: when people lose weight quickly, they don't lose only fat. They also lose muscle mass. Muscle is metabolically critical — it's what helps you maintain weight loss long-term, keeps your metabolism functioning, and protects your health as you age.
Bimagrumab is a monoclonal antibody that works in a completely different way from any GLP-1 medication. It targets activin type II receptors, blocking the signals that tell your body to break down muscle. The result is fat loss while preserving — or even building — lean muscle mass.
In the Phase 2b BELIEVE trial, the combination of bimagrumab and semaglutide achieved 22.1% total body weight loss at 72 weeks, significantly exceeding semaglutide alone (15.7%). But the more remarkable number is this: 92.8% of all weight lost in the combination group came from fat mass. Visceral fat — the dangerous fat around organs — dropped by 58.2%, versus 35.8% with semaglutide alone. Lean muscle mass was reduced by only 2.9% in the combination group, compared to a 7.4% loss with semaglutide alone. Bimagrumab alone actually increased lean mass by 2.5%.
This is not a small distinction. It is the difference between shrinking and actually getting healthier — better metabolic function, better long-term weight maintenance, better physical capacity. An ongoing study in non-diabetic GLP-1 users is expected to report results in 2026. If the data holds, bimagrumab could become a meaningful addition to combination therapy, particularly for older patients, those with diabetes, and anyone who has already noticed muscle loss on a GLP-1 medication.
What This All Means for You
The story of obesity medicine right now is one of diversification. We no longer have a single medication that works reasonably well for most people — we have an expanding toolkit, each with distinct mechanisms, delivery formats, and patient profiles where they shine.
Hate injections? Oral Wegovy or Foundayo may be the right starting point. Need maximum weight loss and can manage a weekly injectable? Tirzepatide remains outstanding today, with retatrutide potentially on the horizon. Concerned about muscle loss, or already on a GLP-1 and noticing strength changes? Bimagrumab-combination therapy may eventually be exactly what we've been waiting for.
Treatment plans will increasingly be personalized — matched not just to how much weight you want to lose, but to your body composition, metabolic profile, lifestyle, and long-term goals. That is precisely the kind of medicine I built Healthy You Endocrinology to practice.
None of this replaces the fundamentals: nutrition quality, movement, sleep, and addressing underlying hormonal or metabolic drivers. But these medications, used thoughtfully by a specialist who knows your full picture, are producing outcomes that simply were not possible five years ago.
If you've been watching from the sidelines, wondering whether now is the right time — the landscape has never been more promising, and I'd love to help you figure out what fits your life.
Ready to get started? Book a consultation at healthyyouendo.com.